SEAL

Trial description
A Phase 2-3, multicenter, randomized, doubleblind study of selinexor (KPT-330) versus placebo in patients with advanced unresectable dedifferentiated liposarcoma (DDLS)
Contact name
Dr James Robin
Trial start date
Wednesday, November 7, 2018
Trial end date
Saturday, August 31, 2019
Trial tumour type
Sarcoma
Show on Radiotherapy
No